Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
A-Z
> ADC PK 분석을 위한 도구 - 항페이로드 항체
| Type | Analyte Detail | Typical Method |
|---|---|---|
| Total Antibody | Conjugated, partially unconjugated, and fully unconjugated (DAR > 0) | Ligand Binding Assay |
| Conjugated Antibody | Antibody with minimum DAR > 1 | Ligand Binding Assay |
| Antibody-conjugated Drug | Total small-molecule drug conjugated to Antibody | Affinity LC-MS / Ligand Binding Assay |
| Unconjugated Drug | Small molecule drug not conjugated to antibody | LC-MS |
| Total Drug | Total unconjugated and conjugated Drug | LC-MS |
ADC molecule type and typical analytical methods for evaluation. 1
Different LBA formats to analyze ADCs in serum 2
| Molecule | Cat. No. | Product Description | Preorder/Order |
|---|
Immobilized Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1, mAb (Cat. No. DXD-M684) at 1 μg/mL, add Trastuzumab deruxtecan in the 50% Human serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).
Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL, add Trastuzumab Deruxtecan in the 100% Human Serum and then add Biotinylated Anti-DXD Antibody, Mouse IgG1, Avitag (Cat. No. DXD-BVM807) at 0.05 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Immobilized Mouse Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) at 5 μg/mL, add Disitamab Vedotin (RC48) in the 50% Mouse serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).
Immobilized Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) at 5 μg/mL, add Trastuzumab-DM1 in the 50% Human serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).
The purity of Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 (Cat. No. DXD-M684) is more than 90% and the molecular weight of this protein is around 135-160 kDa verified by SEC-MALS.
The purity of Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) is more than 90% and the molecular weight of this protein is around 134-163 kDa verified by SEC-MALS.
Immobilized ADC-DXD at 1 μg/mL (100 μL/well) can bind Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1, mAb (Cat. No. DXD-M684) with a linear range of 0.1-4 ng/mL (Routinely tested).
Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) with a linear range of 0.1-2 ng/mL (QC tested).
Immobilized ADC-DM4 at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) with a linear range of 0.20-6.25ng/mL (Routinely tested).
Immobilized ADC-DXD at 1 μg/mL (100 μL/well) can bind HRP conjugated Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1 (Cat. No. DXD-PLM684) with a linear range of 0.5-31 ng/mL (Routinely tested).
| Molecule | Cat. No. | Product Description | Neutralizing activity | Application |
|---|---|---|---|---|
| Adalimu*ab | ADB-Y19 | Anti-Adalimu*ab Antibodies (AY19) | Neutralizing Antibody | ADA assay; Neutralizing assay; Indirect ELISA |
| Adalimu*ab | ADB-Y23b | Anti-Adalimu*ab Antibodies (AY23b) (recommended for PK/PD) | Non-Neutralizing Antibody | PK bridging ELISA; Indirect ELISA |
| Bevacizu*ab | BEB-Y10 | Anti-Bevacizu*ab Antibodies (AY10) (MALS verified, recommended for PK/PD) | Neutralizing Antibody | PK bridging ELISA; Neutralizing assay; Indirect ELISA |
| Bevacizu*ab | BEB-Y12 | Anti-Bevacizu*ab Antibodies (AY12) (recommended for neutralizing assay) | Neutralizing Antibody | ADA assay; Neutralizing assay; Indirect ELISA |
| Bevacizu*ab | BEB-Y9 | Anti-Bevacizu*ab Antibodies (AY9) (recommended for ADA assay) | Neutralizing Antibody | ADA assay; Neutralizing assay; Indirect ELISA |
| Bevacizu*ab | BEB-BY13 | Biotinylated Anti-Bevacizu*ab Antibodies (AY13) (recommended for PK/PD) | Neutralizing Antibody | PK bridging ELISA;Neutralizing assay; Indirect ELISA |
| Cetuxi*ab | CEB-Y27 | Anti-Cetuxi*ab Antibodies (AY27) (recommended for ADA assay) | Neutralizing Antibody | ADA assay; Neutralizing assay; Indirect ELISA |
| Cetuxi*ab | CEB-Y31 | Anti-Cetuxi*ab Antibodies (AY31) (Non-Neutralizing) | Non-Neutralizing Antibody | ADA assay; Indirect ELISA |
| Cetuxi*ab | CEB-Y29 | Anti-Cetuxi*ab Antibodies (AY29) (recommended for PK/PD) | Neutralizing Antibody | PK bridging ELISA; Neutralizing assay; Indirect ELISA |
| Cetuxi*ab | CEB-Y28 | Anti-Cetuxi*ab Antibodies (AY28) | Neutralizing Antibody | ADA assay; Neutralizing assay; Indirect ELISA |
| Cetuxi*ab | CEB-BY31 | Biotinylated Anti-Cetuxi*ab Antibodies (AY31) (recommended for PK/PD) | Non-Neutralizing Antibody | PK bridging ELISA; Indirect ELISA |
| Rituxi*ab | RIB-Y36 | Anti-Rituxi*ab Antibodies (AY36) (recommended for ADA assay) | Neutralizing Antibody | ADA assay;Neutralizing assay; Indirect ELISA |
| Rituxi*ab | RIB-Y37 | Anti-Rituxi*ab Antibodies (AY37) (recommended for PK/PD) | Neutralizing Antibody | PK bridging ELISA;Neutralizing assay;Indirect ELISA |
| Rituxi*ab | RIB-Y35c | Anti-Rituxi*ab Antibodies (MALS verified) | Non-Neutralizing Antibody | ADA assay; Indirect ELISA |
| Trastuzu*ab | TRB-Y5b | Anti-Trastuzu*ab Antibodies (AY5b) (recommended for PK/PD) | Neutralizing Antibody | PK bridging ELISA |
| Trastuzu*ab | TRB-Y1b | Anti-Trastuzu*ab Antibodies (AY1b) (recommended for PK/PD) | Neutralizing Antibody | PK bridging ELISA; Neutralizing assay; Indirect ELISA |
>> Click to learn more core reagents accelerating ADC’s development!
This web search service is supported by Google Inc.
